Definium Therapeutics, Inc. DFTX
34.66 USD +0.02 (+0.07%)
Nov 11, 2026, 1:30 PM EST
33.91 Day range 35.23
10.47 52-week range 49.70
- YTD
- +158.88%
- 1 year
- +177.76%
News
marketbeat.com Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies Definium Therapeutics NASDAQ: DFTX plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive…
seekingalpha.com Definium Q3 Earnings: Psychedelics Approval Beckons But Valuation Seems Inflated Definium Therapeutics, Inc. reported strong Phase 3 results for DT120 in both GAD and MDD, positioning for an NDA filing in H1 2026. DFTX holds over $1bn in cash, supporting operations into 2030, and…
benzinga.com RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $70 RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $66 to $70.
seekingalpha.com Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript
marketbeat.com What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call Definium Therapeutics NASDAQ: DFTX plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3…
benzinga.com Definium Therapeutics Q3 2026 Earnings Call Transcript Definium Therapeutics (NASDAQ:DFTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
businesswire.com Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics…
businesswire.com Definium Therapeutics Announces New Employee Inducement Grants NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address…
businesswire.com Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of…
benzinga.com JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84 JP Morgan initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $84.
benzinga.com Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78 Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
benzinga.com Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79 Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
benzinga.com Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy' Definium Therapeutics announced positive Phase 3 Panorama trial results for DT120 in generalized anxiety disorder patients.
benzinga.com HC Wainwright & Co. Reiterates Buy on Definium Therapeutics, Maintains $70 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $70 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
benzinga.com Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.
benzinga.com Definium Therapeutics Reports Topline Results From Panorama, Second Phase 3 Study Of DT120 ODT In Adults With Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints Study met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3 trial for DT120 ODT in GAD and the third positive Phase 3 trial for DT120 ODTParticipants receiving…- benzinga.com RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.
- benzinga.com Definium To Highlight Phase 3 Data And New Research On Anxiety, Depression At Psych Congress Emerge Phase 3 study podium poster to be featured in "Latest Discoveries & Emerging Trends in MDD" sessionNew epidemiological research on risks associated with anxiety and depression plus five…
- benzinga.com 'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-permanent-roles
benzinga.com Definium Therapeutics Receives FDA Breakthrough Therapy Designation For DT120 ODT; Second Breakthrough Therapy Designation For DT120 Reinforces Its Potential Across MDD And Generalized Anxiety Disorder The designation was supported by the significant unmet medical need in MDD and results from the Company's Phase 3 Emerge study, in which a single 100 µg dose of DT120 ODT demonstrated a statistically…
benzinga.com This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top analysts changed outlook on top names. See analyst ratings page for all changes.- benzinga.com B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75 B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
- benzinga.com Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90 Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $74 to $90.
- benzinga.com Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64 Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.
benzinga.com RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66 RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $66.- benzinga.com Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72 Wells Fargo analyst Benjamin Burnett maintains Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $68 to $72.
- benzinga.com Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75 Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $75.
benzinga.com Needham Maintains Buy on Definium Therapeutics, Raises Price Target to $66 Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $66.
benzinga.com Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar' Definium Therapeutics says positive Phase 3 trial results for DT120, shows significant and rapid symptom improvement in anxiety participants.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics- benzinga.com Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints Topline results from Voyage, its first Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 µg in adults with generalized anxiety disorder (GAD). The results mark the Company’s…
- benzinga.com Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $75 Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $73 to $75.
- benzinga.com Wells Fargo Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $68 Wells Fargo analyst Benjamin Burnett initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $68.
- benzinga.com Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $73 Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $48 to $73.
benzinga.com Why Is GH Research Stock Trading Higher on Thursday? GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.- benzinga.com Definium Therapeutics Announces Launch Of Wired For Worry, New Healthcare Provider Disease Education Initiative Focused On Generalized Anxiety Disorder GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3Patients experience high rates of pharmacotherapy switching,…
- benzinga.com Definium Therapeutics Study Shows High Discontinuation In GAD, Spotlighting Need For Improved Efficacy And Tolerability Data highlight the challenges of achieving response and sustained remission in newly diagnosed and established GAD patients with existing therapiesDefinium Therapeutics, Inc. (NASDAQ:DFTX)…
- benzinga.com Stifel Maintains Buy on Definium Therapeutics, Raises Price Target to $60 Stifel analyst Paul Matteis maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $30 to $60.
- benzinga.com Canaccord Genuity Maintains Buy on Definium Therapeutics, Lowers Price Target to $58 Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and lowers the price target from $60 to $58.
benzinga.com Top 3 Health Care Stocks That May Keep You Up At Night In June Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.
benzinga.com Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.- benzinga.com Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $74 Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $61 to $74.
benzinga.com What's Going On With Definium Therapeutics Stock Tuesday? Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.
benzinga.com Micron Technology To $1,500? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. Complete view of changes, incl. upgrades/downgrades, on analyst ratings page.- benzinga.com Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $57 Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $37 to $57.
- benzinga.com Needham Maintains Buy on Definium Therapeutics, Raises Price Target to $50 Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $38 to $50.
- benzinga.com Definium Therapeutics Plans To Commence $500M Common Stock Offering Definium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying…
- benzinga.com Leerink Partners Maintains Outperform on Definium Therapeutics, Raises Price Target to $52 Leerink Partners analyst Marc Goodman maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $30 to $52.
- benzinga.com Oppenheimer Maintains Outperform on Definium Therapeutics, Raises Price Target to $60 Oppenheimer analyst Jay Olson maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $40 to $60.